Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure

dc.contributor.authorSemmler, Georg
dc.contributor.authorAlonso Lopez, Sonia
dc.contributor.authorPons, Monica
dc.contributor.authorLens García, Sabela
dc.contributor.authorDajti, Elton
dc.contributor.authorGriemsmann, Marie
dc.contributor.authorZanetto, Alberto
dc.contributor.authorBurghart, Lukas
dc.contributor.authorHametner-Schreil, Stefanie
dc.contributor.author Hartl, Lukas
dc.contributor.authorManzano, Marisa
dc.contributor.authorRodríguez Tajes, Sergio
dc.contributor.authorZanaga, Paola
dc.contributor.authorSchwarz, Michael
dc.contributor.authorGutierrez, María L.
dc.contributor.authorJachs, Mathias
dc.contributor.authorPocurull Aparicio, Anna
dc.contributor.authorPolo Lorduy, Benjamín
dc.contributor.authorEcker, Dominik
dc.contributor.authorMateos, Beatriz
dc.contributor.authorIzquierdo, Sonia
dc.contributor.authorReal, Yolanda
dc.contributor.authorBalcar, Lorenz
dc.contributor.authorCarbonell-Asins, Juan A.
dc.contributor.authorGschwantler, Michael
dc.contributor.authorRusso, Francesco P.
dc.contributor.authorAzzaroli, Francesco
dc.contributor.authorMaasoumy, Benjamin
dc.contributor.authorReiberger, Thomas
dc.contributor.authorForns Bernhardt, Xavier
dc.contributor.authorGenescà, Joan
dc.contributor.authorBañares, Rafael
dc.contributor.authorMandorfer, Mattias
dc.contributor.authorcACLD-SVR Study Group
dc.date.accessioned2026-03-02T15:30:03Z
dc.date.available2026-03-02T15:30:03Z
dc.date.issued2025-02-01
dc.date.updated2026-03-02T09:28:37Z
dc.description.abstractBackground & Rationale: Around 750.000 patients/year will be cured from hepatitis C-virus (HCV)-infection until 2030. Those with compensated advanced chronic liver disease (cACLD) remain at risk for hepatic decompensation and de-novo hepatocellular carcinoma (HCC). Algorithms have been developed to stratify risk early after cure, however, data on long-term outcome and the prognostic utility of these risk stratification algorithms at later timepoints are lacking. Main Results: We retrospectively analysed a cohort of 2335 cACLD-patients (LSM >= 10kPa) who achieved HCV-cure by interferon-free therapies from 15 European centres (median age 60.2 +/- 11.9 y, 21.1% obesity, 21.2% diabetes). During a median follow-up of 6 years, first hepatic decompensation occurred in 84 patients (3.6%, incidence rate [IR]: 0.74%/year, cumulative incidence at 6 y: 3.2%); 183 (7.8%) patients developed de-novo HCC (IR: 1.60%/year, cumulative incidence at 6 y: 8.3%), with both risks being strictly linear over time. Baveno VII criteria to exclude (FU-LSM 150 G/L) or rule-in (FU-LSM >= 25kPa) clinically significant portal hypertension (CSPH) stratified the risk of hepatic decompensation with proportional hazards. Estimated probability of CSPH discriminated patients developing versus not developing hepatic decompensation in the grey-zone (i.e., patients meeting none of the above criteria). Published HCC risk stratification algorithms identified high- and low-incidence groups, however, the size of the latter group varied substantially (9.9%-69.1%). A granular 'HCC-SVR' model was developed to inform on an individual patient's HCC-risk after HCV-cure. Conclusion: In patients with cACLD, the risks of hepatic decompensation and HCC remain constant after HCV-cure, even in the long-term (>3 y). One-time post-treatment risk stratification based on non-invasive criteria provides important prognostic information that is maintained during long-term follow-up, as the hazards remain proportional over time.
dc.format.extent51 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idimarina9447539
dc.identifier.issn1527-3350
dc.identifier.pmid39817915
dc.identifier.urihttps://hdl.handle.net/2445/227774
dc.language.isoeng
dc.publisherAmerican Association for the Study of Liver Diseases
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1097/HEP.0000000000001005
dc.relation.ispartofHEPATOLOGY, 2025, vol. 81, num. 2, p. 609-624
dc.relation.urihttps://doi.org/10.1097/HEP.0000000000001005
dc.rights(c) Wolters Kluwer Health, 2025
dc.sourceArticles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
dc.subject.classificationInfeccions per coronavirus
dc.subject.classificationCirurgia hepàtica
dc.subject.classificationHepatitis
dc.subject.otherCoronavirus infections
dc.subject.otherLiver surgery
dc.subject.otherHepatitis
dc.titleLong-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
SEMMLERALONSOLOPEZ_LONGTERM_RISK__unificat.2pdf.pdf
Mida:
622.01 KB
Format:
Adobe Portable Document Format